Finance

Beta
Lists
GIS:FRA
Gilead Sciences, Inc
€110.84
-0.75%
(-0.84) 1D
Jun 4, 8:04:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
€111.24
High
€111.88
Low
€110.84
Mkt. cap
160.81B
Avg. vol.
358.00
Volume
185.00
52-wk high
€132.00
52-wk low
€90.00
No. of employees
17K
Open
€111.24
High
€111.88
Low
€110.84
Mkt. cap
160.81B
Avg. vol.
358.00
Volume
185.00
52-wk high
€132.00
52-wk low
€90.00
No. of employees
17K
News stories
From sources across the web
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy. In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade. In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100. The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
7.08B
7.77B
7.92B
6.96B
Cost of goods sold
1.50B
1.57B
1.62B
1.44B
Cost of revenue
1.50B
1.57B
1.62B
1.44B
Research and development expenses
1.45B
1.33B
1.57B
1.36B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.36B
1.35B
1.78B
1.43B
Operating expense
2.81B
2.69B
3.34B
2.78B
Total operating expenses
4.31B
4.26B
4.96B
4.23B
Operating income
2.77B
3.51B
2.96B
2.73B
Other non operating income
13.00M
-23.00M
51.00M
-8.00M
EBT including unusual items
2.43B
3.64B
2.08B
2.58B
EBT excluding unusual items
2.58B
3.34B
2.80B
2.59B
Income tax expense
468.00M
589.00M
-105.00M
559.00M
Effective tax rate
19.28%
16.18%
-5.05%
21.67%
Other operating expenses
-
-
-
-
Net income
1.96B
3.05B
2.18B
2.02B
Net profit margin
27.68%
39.28%
27.55%
29.04%
Earnings per share
2.01
2.47
1.86
2.03
Interest and investment income
73.00M
88.00M
95.00M
95.00M
Interest expense
-254.00M
-256.00M
-255.00M
-240.00M
Net interest expenses
-181.00M
-168.00M
-160.00M
-145.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.46B
4.20B
3.65B
3.42B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer